Abstracts plan in US covering 4 million lives. Outcomes measure was any occurrence of CV including ischemic heart disease, cerebrovascular disease, and peripheral vascular disease. A multivariate logistic model was developed to evaluate adjusted CV-risk. Multicollinearity test and Hosemer-Lemeshow test were performed. RESULTS: Mean( / SD) age was 57( / 8) years in combo-group(N 53) and 57( / 11) years in mono-group(N 5670). In combo-group, mean( / SD) treatment-duration was 779( / 424) days for statin fi brate combination-therapy. In mono-group, mean( / SD) treatment-duration was 987( / 588) days for statin-monotherapy. Unadjusted CV-rates of combo-group versus mono-group were not signifi cantly different (odds ratio [OR] 1.39, P 0.2313). Although adjusting for age, gender, prior CV, CV related pharmacy-costs, total medical-costs, diabetes with complication, and Elixhauser-comorbidity, CV-rates of combo-group versus mono-group were not signifi cantly different (OR 1.186, P 0.5929). All covariates were signifi cantly associated with CV-rates. The model did not suffer from multicollinearity and the model goodness-of-fi t was satisfactory (P 0.5575). CONCLUSIONS: In a managed care population with type-II diabetes after adjusting for known baseline differences, CVrisks among subjects who used statin fi brate combination-therapy compared to those who used statin-monotherapy did not signifi cantly differ. This is different from what people expected for the combination-therapy, due to low power resulting from small sample size for combo-group. We hope this result will be useful in health policy to fi nd treatment strategies to reduce CV-risk in diabetics. Future research is in progress to address the causality behind this association.
cohort study utilizing national Veterans Affairs electronic medical records. The cohort consisted of all heart failure patients diagnosed between October 1, 1997 to September 30, 2002 . After excluding patients with any exposure to ARBs within the previous 6 months, new exposure to ARBs was determined between the index date (October 1, 2000) and the study end date (September 30, 2002) and subsequent time to death was measured concurrently during that period. Five treatment groups were defi ned based on initial use of: Candesartan, Valsartan, Losartan, Irbesartan, and Telmisartan. Multiple Cox proportional hazards regression analysis was employed to assess the adjusted association between these treatments and time to death after controlling for demographics, hospitalization, years with CHF, 30 comorbidities and comedications. Losartan was chosen as the reference drug because it was the fi rst ARB introduced into the market. RESULTS: Total 19,186 patients were identifi ed. Majority of the patients were male (98.06%).The most common comorbid condition in the cohort was hypertension(81.17%) followed by Ischemic Heart Disease(68.65%) and diabetes(48.46%). Irbesartan (55.50%) was the most commonly prescribed ARB followed by Losartan (19.44%) . In the multivariable model losartan was found to have a statistically signifi cant decreased risk as compared to telmisartan, adjusted hazard ratio for telmisartan was 1.66 (95% CI: 1.12 -2.46).Irbesartan, Valsartan, and Candesartan were not statistically signifi cantly different from Losartan. CONCLUSIONS: All of the ARBs had similar associations with time to death, except telmisartan, which had a statistically increased risk of mortality within two years. Further research is needed to examine other outcomes including cost-effectiveness in the treatment of heart failure.
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POINT-OF-CARE INR MONITORING DEVICES FOR PATIENTS ON LONG-TERM ORAL ANTICOAGULATION THERAPY
Khan T Ontario Ministry of Health and LongTerm Care, Toronto, ON, Canada OBJECTIVES: To assess the clinical effectiveness of point-of-care (POC) INR monitoring devices for patient on long-term oral anticoagulation therapy (OAT). METHODS: A systematic review of the clinical literature was performed. Seventeen RCT studies published between January 1996 and November 2008 comparing POC devices to routine anticoagulation control were included in the analysis. RESULTS: Of the 17 studies included in the analysis, 15 studies compared patient self-management or selftesting to routine anticoagulation control and 2 studies examined the use of POC devices by primary health care practitioners. There was variation among the studies regarding observation periods, indication for OAT and overall study quality. Based on pooled analyses, there was no signifi cant difference in major hemorrhagic events between patients in POC monitoring groups and usual care controls (OR 0.77, 95% CI 0.54, 1.10). POC monitoring resulted in signifi cantly fewer thromboembolic events (OR 0.56, 95% CI 0.39, 0.80) and deaths (OR 0.63, 95% CI 0.41, 0.97) compared with usual care. Subgroup analyses included POC strategy, control strategy, indication for OAT, study quality, length of follow-up and industry sponsored. Mean time in the therapeutic range was pooled across studies and weighted by the number of patientyears of observation to assess INR control. The POC monitoring patients were in range 68.6% of the time compared with 64.3% of time in usual care controls. Data were deemed unreliable to estimate 95% CI for pooled estimates. Higher testing frequency and more intensive patient education in the POC monitoring groups may also partially explain observed differences in clinical outcomes. CONCLUSIONS: The review of clinical evidence suggest that using POC monitoring devices for patients on long-term OAT results in signifi cantly fewer deaths and thromboembolic events and may result in better INR control than conventional laboratory testing. Nevertheless, the use of POC devices should factor patient suitability, health system constraints and affordability.
PCV12 FONDAPARINUX IS ECONOMICALLY NON-INFERIOR TO ENOXAPARIN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM
Bonafede MM 1 , Shorr AF 2 , Johnson BH 1 , Horblyuk R 3 1 Thomson Reuters, Cambridge, MA, USA, 2 Washington Hospital Center, Washington, DC, USA, 3 GlaxoSmithKline, Philadelphia, PA, USA OBJECTIVES: Fondaparinux was shown to be non-inferior to enoxaparin in treatment of deep vein thrombosis (DVT) in a clinical trial setting. Comparisons of outcomes between these agents for treatment of DVT or pulmonary embolism (PE) in a naturalistic setting are not known. Objective of this study was to evaluate real-world economic outcomes of fondaparinux vs. enoxaparin for inpatient treatment of venous thromboemolism (VTE). METHODS: Retrospective analysis of discharge data from over 550 US acute care hospitals was conducted to evaluate and compare economic outcomes of patients receiving fondaparinux or enoxaparin for VTE treatment. Discharges containing ICD-9 diagnosis codes for VTE (DVT, PE or both) were included. Total hospital charges and index anticoagulant charges were captured for initial admission and any readmissions for VTE within 30-day follow-up. Demographic, clinical, and hospital descriptive measures were used to compare two treatment cohorts and to inform multivariate models. Expenditures in fondaparinux and enoxaparin cohorts were compared using a generalized linear methods (GLM) approach. RESULTS: Fondaparinux patients (n 366) were younger (61 vs. 64, p 0.001) than enoxaparin patients (n 14,674) and had more severe illness profi les (APR DRG 3.18 vs. 3.07, p 0.024). Average unadjusted charges for initial admission across the two groups were $76,352. Adjusted difference in charges for initial admission between fondaparinux and enoxaparin was not statistically signifi cant (difference $574; p 0.906). Average unadjusted charges for overall study period including 30day follow-up were $80,764. Adjusted difference in charges between two groups was not statistically signifi cant (difference $3,633; p 0.536). Charges for index anticoagulant during initial admission were $2233 for fondaparinux and $2497 for enoxaparin (p 0.108). After multivariate adjustment, this difference was signifi cantly lower in favor of fondaparinux (difference $409, p 0.001). CONCLUSIONS: These real-world economic outcomes corroborate clinical trial fi ndings supporting noninferiority of fondaparinux compared to enoxaparin for VTE treatment, as measured by hospital charges. Further analyses of clinical outcomes in a naturalistic setting are warranted.
